Tao Yun-Yun, Shi Yue, Gong Xue-Qin, Li Li, Li Zu-Mao, Yang Lin, Zhang Xiao-Ming
Medical Imaging Key Laboratory of Sichuan Province, Interventional Medical Center, Department of Radiology, Medical Research Center, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China.
Department of Pathology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China.
Cancers (Basel). 2023 Jan 5;15(2):365. doi: 10.3390/cancers15020365.
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumour and the third leading cause of cancer death in the world. The emerging field of radiomics involves extracting many clinical image features that cannot be recognized by the human eye to provide information for precise treatment decision making. Radiomics has shown its importance in HCC identification, histological grading, microvascular invasion (MVI) status, treatment response, and prognosis, but there is no report on the preoperative prediction of programmed death ligand-2 (PD-L2) expression in HCC. The purpose of this study was to investigate the value of MRI radiomic features for the non-invasive prediction of immunotherapy target PD-L2 expression in hepatocellular carcinoma (HCC). A total of 108 patients with HCC confirmed by pathology were retrospectively analysed. Immunohistochemical analysis was used to evaluate the expression level of PD-L2. 3D-Slicer software was used to manually delineate volumes of interest (VOIs) and extract radiomic features on preoperative T2-weighted, arterial-phase, and portal venous-phase MR images. Least absolute shrinkage and selection operator (LASSO) was performed to find the best radiomic features. Multivariable logistic regression models were constructed and validated using fivefold cross-validation. The area under the receiver characteristic curve (AUC) was used to evaluate the predictive performance of each model. The results show that among the 108 cases of HCC, 50 cases had high PD-L2 expression, and 58 cases had low PD-L2 expression. Radiomic features correlated with PD-L2 expression. The T2-weighted, arterial-phase, and portal venous-phase and combined MRI radiomics models showed AUCs of 0.789 (95% CI: 0.702-0.875), 0.727 (95% CI: 0.632-0.823), 0.770 (95% CI: 0.682-0.875), and 0.871 (95% CI: 0.803-0.939), respectively. The combined model showed the best performance. The results of this study suggest that prediction based on the radiomic characteristics of MRI could noninvasively predict the expression of PD-L2 in HCC before surgery and provide a reference for the selection of immune checkpoint blockade therapy.
肝细胞癌(HCC)是全球第六大常见恶性肿瘤,也是癌症死亡的第三大主要原因。新兴的放射组学领域涉及提取许多人眼无法识别的临床图像特征,以为精确治疗决策提供信息。放射组学已在HCC的识别、组织学分级、微血管侵犯(MVI)状态、治疗反应和预后方面显示出其重要性,但尚无关于HCC中程序性死亡配体-2(PD-L2)表达术前预测的报道。本研究的目的是探讨MRI放射组学特征对肝细胞癌(HCC)免疫治疗靶点PD-L2表达进行无创预测的价值。回顾性分析了108例经病理确诊的HCC患者。采用免疫组织化学分析评估PD-L2的表达水平。使用3D-Slicer软件手动勾勒感兴趣体积(VOIs),并在术前T2加权、动脉期和门静脉期MR图像上提取放射组学特征。采用最小绝对收缩和选择算子(LASSO)来寻找最佳的放射组学特征。构建多变量逻辑回归模型,并使用五折交叉验证进行验证。采用受试者工作特征曲线下面积(AUC)评估各模型的预测性能。结果显示,在108例HCC病例中,50例PD-L2高表达,58例PD-L2低表达。放射组学特征与PD-L2表达相关。T2加权、动脉期、门静脉期及联合MRI放射组学模型的AUC分别为0.789(95%CI:0.702-0.875)、0.727(95%CI:0.632-0.823)、0.770(95%CI:0.682-0.875)和0.871(95%CI:0.803-0.939)。联合模型表现最佳。本研究结果表明,基于MRI放射组学特征的预测可以在术前无创预测HCC中PD-L2的表达,为免疫检查点阻断治疗的选择提供参考。